The award supports selected faculty during the crucial period of career development, spanning completion of research training through the early years of their first faculty position held at Weill Cornell Medicine.
The study has yielded breakthroughs to help illuminate a growing body of evidence that gut microbial metabolites play a critical role in mucosal immunity and inflammation.
The paper opens a new window on the control of blood glucose levels through the liver via gut microbiome.
The grant will fund critical studies on HPV-related cancers in people living with HIV and will include clinical trials focused on two forms of cancer – oropharyngeal and cervical.
Dr. Lo and colleagues hope that by using adipsin or DUSP26 therapies, patients with type 2 diabetes will be spared from developing beta cell failure and thus spared from insulin injections.
In a collaborative study, Dr. John R. Lee and colleagues revealed a first-of-its-kind discovery showing that the abundance of uropathogens in the gut is associated with future development of UTI.
Funded by a $22 million grant from the National Institutes of Health and Three Lakes Partners, the PRECISIONS study aims to transform diagnosis and treatment for idiopathic pulmonary fibrosis.
Results of a recent study that used a new drug combination (glecaprevir/pibrentasivr) for chronic HCV and compensated cirrhosis of the liver, showed high virological cure rates.
The grant seeks to understand the opportunities and challenges posed by cognitive restoration for people with severe to moderate traumatic brain injury in the context of the Americans with Disabilities Act.
Dr. Melnick and his team have developed an SIRT3-blocking compound that rapidly kills diffuse large B cell lymphoma cells in the culture dish and in mice.